Welcome to our dedicated page for Fmc SEC filings (Ticker: FMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The FMC Corporation (NYSE: FMC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a global agricultural sciences company focused on crop protection, biologicals, crop nutrition, and digital and precision agriculture, FMC uses its SEC reports to detail its financial condition, restructuring activities, capital structure and governance.
Investors can review current reports on Form 8-K, where FMC discloses material events such as quarterly earnings releases, leadership changes, restructuring initiatives and credit agreement amendments. For example, the company has filed 8-Ks describing quarterly financial results, the comprehensive Project Foundation cost optimization plan and Manufacturing Restructuring Program, and an amendment to its Fifth Amended and Restated Credit Agreement that adjusts leverage and interest coverage covenants and places conditions on dividends and indebtedness.
Through its periodic annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR and summarized on this page), FMC provides more detailed information on revenue by region, cost structure, research and development spending on new herbicide, insecticide and fungicide active ingredients, and risks related to competition, regulation and restructuring. These filings also describe the company’s geographic footprint, including its headquarters in Philadelphia, Pennsylvania, and its operations across North America, Latin America, Asia and EMEA.
The filings page also highlights governance and board-related disclosures, such as 8-K reports on director resignations or executive departures, and may include proxy materials that discuss executive compensation and board composition. For those monitoring capital structure and liquidity, filings related to credit facilities, covenant changes and potential asset sales—such as the planned divestiture of the India commercial business—are particularly relevant.
Stock Titan enhances these documents with AI-powered summaries that explain key points in plain language, helping users interpret complex sections of lengthy 10-Ks, 10-Qs and 8-Ks. Real-time updates from EDGAR ensure that new filings, including any Form 4 insider transaction reports or additional restructuring disclosures, appear promptly so investors can track how FMC’s financial and strategic decisions evolve over time.
FMC Corporation director Margareth Oevrum reported the acquisition of 103 shares of common stock on January 15, 2026. The shares were issued at $0 per share pursuant to dividend equivalent rights connected to vested restricted stock units held by her. Following this issuance, she directly owns 22,409 FMC common shares.
FMC Corporation director Robert C. Pallash received additional equity compensation in the form of common stock. On January 15, 2026, he acquired 306 shares of FMC common stock at a price of $0.00 per share through dividend equivalent rights connected to vested restricted stock units held by him. After this transaction, he directly beneficially owned 60,422 FMC common shares. This was a Form 4 filing by a single reporting person in his capacity as a director, reflecting a routine equity-based compensation accrual rather than an open‑market trade.
FMC director John Mitchell Raines reported a small equity award in the form of company stock. On January 15, 2026, he acquired 20 shares of FMC common stock at a price of $0 per share, bringing his total directly held FMC shares to 13,804 after the transaction. The shares were issued pursuant to dividend equivalent rights tied to previously vested restricted stock units, meaning he received additional shares in lieu of cash dividends on those vested awards.
FMC Corporation director Patricia Verduin reported a small stock acquisition through dividend equivalents. On 01/15/2026, she acquired 22 shares of FMC common stock in a transaction coded "A" at a price of $0 per share. According to the footnote, these shares were issued pursuant to dividend equivalent rights tied to vested restricted stock units she already held, meaning they represent dividends paid in stock rather than a market purchase. After this transaction, she beneficially owns 7,133 FMC common shares, held directly.
FMC Corporation reported a small insider share acquisition by its Chairman, CEO and President, Pierre R. Brondeau. On 01/15/2026, he acquired 36 shares of FMC common stock at a price of $0.00 per share. According to the footnote, these shares were issued as dividend equivalent rights tied to vested restricted stock units he already held, rather than a market purchase.
Following this issuance, Brondeau directly beneficially owned 300,906 shares of FMC common stock. The transaction was reported on a Form 4 filed for a single reporting person and reflects routine equity-based compensation rather than an open-market trade.
FMC Corporation reported an insider equity transaction involving a director. On 12/31/2025, the director had a transaction in Common Stock coded "F" for 73 shares disposed of at a price of $13.98 per share. Following this transaction, the director beneficially owned 31,546 shares of FMC Corporation common stock, held as direct ownership.
FMC Corporation director reports small share transaction. A company director filed a statement of beneficial ownership showing a transaction in FMC common stock dated 12/31/2025. The filing reports the disposition of 73 shares of common stock at a price of $13.98 per share under transaction code "F," which typically indicates a tax-related transaction associated with equity awards. Following this activity, the director reports beneficial ownership of 56,460 shares of FMC common stock held directly.
FMC Corporation disclosed that a director reported a small change in ownership of the company’s common stock. On 01/02/2026, the director had a transaction in common stock coded “F” in the filing, involving the disposition of 73 shares at a price of $13.87 per share.
After this transaction, the director’s beneficial ownership in FMC common stock stood at 34,923 shares, held directly. No derivative securities transactions were reported, and the filing indicates it was submitted by a single reporting person.
FMC Corporation has approved Project Foundation, a broad restructuring and manufacturing optimization program intended to lower costs and streamline its operations.
The company expects these actions to deliver $175 million or more of annual run-rate savings by the end of 2027. To implement the program, FMC plans to incur $560 to $635 million in pre-tax restructuring charges, including $420 to $440 million of non-cash asset write-offs and accelerated depreciation, and $140 to $195 million of cash costs such as $50 to $80 million of severance, $10 to $20 million of consulting fees, and $80 to $95 million of decommissioning and contract termination charges.
Following a significant decline in its stock price, FMC is required to test goodwill and other intangible assets for impairment for the year ending December 31, 2025 and, absent a stock price recovery, expects to record a significant non-cash impairment, which it states will not affect cash flows from current or future operations.
FMC Corporation entered into Amendment No. 5 to its Fifth Amended and Restated Credit Agreement with Citibank and other lenders. The amendment adjusts the leverage ratio and minimum interest coverage covenants during a covenant relief period that now runs until the earlier of December 31, 2028 or an elected early termination. During this period, subsidiary indebtedness is capped at an aggregate outstanding principal amount of $350 million, subject to exceptions.
The amendment also restricts increases to FMC’s regular quarterly dividend above $0.08 per share and limits any other dividends unless FMC meets a pro forma leverage ratio of no more than 3.75 to 1:00. In addition, FMC must maintain at least $1 billion in the aggregate value of specified qualifying intellectual property, and it will be required to grant a lien over substantially all of its assets if it receives public debt ratings from any two of S&P, Fitch or Moody’s below BB+ (S&P, Fitch) or Ba1 (Moody’s).